🧾 What This Document Is

This is a Form 8-K filing, which a company uses to announce major news to investors. Attached to it is a press release (Exhibit 99.1) giving the details. In simple terms, Picard Medical is sharing its preliminary revenue results for the first three months of 2026 before the full, official financial report is ready.

👉 Key Takeaway: This is an early look at sales numbers, not the final, audited financials. Think of it as a "flash report" to update the market.

🏢 What The Company Does

Picard Medical, Inc. is the parent company of SynCardia Systems. In simple terms, they make and sell the world's first and only total artificial heart approved for use in the U.S. and Canada. It's a life-saving device for patients with end-stage heart failure, acting as a bridge until a human donor heart becomes available.

👉 Key Takeaway: This is a highly specialized medical device company with a unique, life-critical product in a niche market.

💰 Financial Highlights

The big news is significant top-line growth. Here are the key numbers for Q1 2026:

• Revenue: $1.1 million
• Growth: Up 79.9% from $0.6 million in Q1 2025.
• What Drove the Growth:
  1. Higher Sales: More of their artificial heart devices were used.
  2. Pricing Power: They increased the price for renting the "driver" machine (the external pump that powers the artificial heart), which generates ongoing revenue.

👉 Key Takeaway: The company nearly doubled its quarterly revenue, driven by both selling more units and earning more from each installation through rental fees.

🚀 Key Moves & Strategy

The growth isn't random; it's the result of focused efforts. The CEO, Patrick NJ Schnegelsberg, highlighted progress in commercial operations (how they sell and support the product) and noted that favorable reimbursement conditions in the U.S. helped. Looking forward, they are focused on expanding patient access and developing their next-generation, fully implantable artificial heart.

👉 Key Takeaway: The company is capitalizing on current success to fund R&D for a future, more advanced product, which is key for long-term growth.

📦 Financial Position & Caveats

This press release comes with a major warning. The revenue figures are preliminary and unaudited. They are based on information available as of April 22, 2026, and are still subject to the company's normal quarterly closing and review process. The actual numbers in the official 10-Q report could be different.

👉 Key Takeaway: Treat these numbers as a strong indicator, not the final word. The complete picture, including expenses and profits, will come with the full 10-Q report expected by May 15, 2026.

🔮 What's Next & Market Context

The company is the dominant player in its field, with over 2,100 implants across 27 countries. Their focus on the U.S. market and strategic pricing appears to be working. The next major milestone for investors will be the release of the full quarterly report, which will show not just revenue but also costs, profitability, and cash flow.

👉 Key Takeaway: They are executing in their core market while building the next technological platform. Success depends on continued adoption and navigating the complex, high-cost healthcare system.

⚖️ Big Picture: Strengths & Risks

• 👍 Strengths: Unique, FDA-approved product with a proven track record; strong revenue growth; clear strategy for innovation.
• ⚠️ Risks: Operates in a highly regulated industry; product success depends on hospital adoption and insurance reimbursement; the company is still relatively small (with quarterly revenue in the millions); future development of a fully implantable heart is complex and expensive.

🧠 The Analogy

Think of Picard Medical like a company that makes the only approved jetpack for emergency rescues. They just reported that more people used their jetpacks this quarter, and they also raised the fee for renting the essential fuel pack that comes with it. Everyone is waiting to see if they can build an even better, self-contained jetpack next.

🧩 Final Takeaway

Picard Medical showed impressive 79.9% revenue growth thanks to higher demand and better pricing for its life-saving artificial heart system. This is a positive signal of commercial traction, but remember these are unaudited preliminary numbers. The full financial story will emerge in the 10-Q filing due by mid-May.